Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on May 7, 2020. The report details the closing of a private placement financing transaction previously announced on April 27, 2020.
Key Financial Metrics
- Capital Raised: $5.0 million in aggregate proceeds.
- Shares Issued: 1,225,490 shares of Common Stock.
- Purchase Price: $4.08 per share (based on the average closing price over the 10 trading days preceding the agreement).
- Investors: Winsave Resources Limited and Pioneer Step Holdings Limited.
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics; it focuses solely on the equity transaction.
Material Changes
The primary material change is the increase in outstanding common stock by 1,225,490 shares and the corresponding increase in cash assets from the $5.0 million financing. This transaction was executed under an exemption from registration requirements (Section 4(a)(2) and Rule 506 of Regulation D).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the shares were sold to accredited investors for investment purposes and not for resale. No unusual items or contingencies are reported in this specific document.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the use of proceeds from the $5.0 million financing in subsequent filings or press releases.
- Review the accreditation status of the purchasers (Winsave Resources Limited and Pioneer Step Holdings Limited) as disclosed.
- Check for any lock-up agreements or resale restrictions associated with the unregistered shares.